HOME >> BIOLOGY >> NEWS
Clinical study reports findings of combination therapy with DOXIL

h as improvement in disease-related symptoms or increased survival.

How DOXIL Works
DOXIL is an advanced form of doxorubicin, a liposomal formulation of doxorubicin, which means that doxorubicin is encapsulated by a fatty bilayer. The liposome is pegylated, which helps protect the drug from the immune system, resulting in the product circulating in the blood for a longer period of time. The longer circulation allows dosing once every four weeks.

Administration
DOXIL is administered intravenously in the doctor's office or clinic. Treatment usually takes from 30 minutes to one hour, though the first treatment may be longer.

  • To manage adverse events such as PPE, stomatitis, or hematologic toxicity, the dose may be delayed or reduced;
  • Pretreatment with or concomitant use of antiemetics should be considered; and
  • Limited clinical experience exists in treating hepatically impaired patients with DOXIL. Based on experience with doxorubicin HCl, it is recommended that DOXIL dosage be reduced if the bilirubin is elevated as follows: Serum bilirubin 1.2 to 3.0 mg/dL give normal dose, >3.0 mg/dL give normal dose.

Efficacy
DOXIL's refractory ovarian cancer indication was based on the results of three Phase II trials involving patients with metastatic ovarian cancer that was resistant to conventional chemotherapy. Most of the patients had been treated with two or more rounds of conventional chemotherapy, but the tumor was still progressing.

In these studies, patients with refractory metastatic ovarian cancer treated with DOXIL had a 13.8% (20/145) (95% CI 8.1% to 19.3%) combined response rate. The median time to response was 18 weeks, median duration of response was 39 weeks, and median time to disease progression was 16 weeks.

Warnings
In clinical trials, the most common side effects reported with DOXIL therapy included reduced red blood cel
'"/>


8-May-2003


Page: 1 2 3 4 5 6

Related biology news :

1. Creation of the UK Clinical Research Collaboration will boost clinical trials in UK
2. Clinical judgement still counts strongly alongside genetic testing
3. Jay Levy honored with 2004 Abbott Laboratories Award in Clinical and Diagnostic Immunology
4. Melvin Weinstein wins 2004 BD Award for Research in Clinical Microbiology
5. DFG to establish seven new Clinical Research Units
6. Clinical trial patients dont care about study sponsors or physician conflicts of interest
7. NIH establishes Rare Diseases Clinical Research Network
8. Clinical study results published in NEJM show promising data on Antegren (natalizumab)
9. Clinical trial shows timing of chemotherapy improves survival in breast cancer
10. Clinical services must catch up
11. Clinical Advances towards the simplification if HIV therapy: First once-daily dosing results for the HIV protease inhibitor, Agenerase

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... 17, 2016 ABI Research, the leader ... global biometrics market will reach more than $30 ... from 2015. Consumer electronics, particularly smartphones, continue to ... anticipated to reach two billion shipments by 2021 ... Pavlakis , Research Analyst at ABI Research. "Surveillance ...
Breaking Biology News(10 mins):
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/29/2016)... ... April 29, 2016 , ... Intelligent Implant Systems announced today that ... 510(k) for sale in the United States. These components expand the capabilities of ... With one-level sales beginning in October of 2015, the company has seen significant sales ...
(Date:4/28/2016)... , April 28, 2016 ... company reports the Company,s CEO  was featured in ... Accelerators Enter When VCs Fear To Tread: ... Leader magazine is an essential business ... everything from emerging biotechs to Big Pharmas. Their ...
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
Breaking Biology Technology:
Cached News: